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A B S T R A C T
Systemic anaplastic large cell lymphoma (ALCL) is a distinct disease classiﬁcation provisionally sub-divided
into ALCL, Anaplastic Lymphoma Kinase (ALK)+ and ALCL, ALK entities. More recently, another category of
ALCL has been increasingly reported in the literature and is associated with the presence of breast implants.
A comprehensive review of the 71 reported cases of breast implant associated ALCL (iALCL) is presented
indicating the apparent risk factors and main characteristics of this rare cancer. The average patient is 50
years of age and most cases present in the capsule surrounding the implant as part of the periprosthetic
ﬂuid or the capsule itself on average at 10 years post-surgery suggesting that iALCL is a late complication.
The absolute risk is low ranging from 1:500,000 to 1:3,000,000 patients with breast implants per year. The
majority of cases are ALK-negative, yet are associated with silicone-coated implants suggestive of the
mechanism of tumorigenesis which is discussed in relation to chronic inﬂammation, immunogenicity of
the implants and sub-clinical infection. In particular, capsulotomy alone seems to be sufﬁcient for the
treatment of many cases suggesting the implants provide the biological stimulus whereas others require
further treatment including chemo- and radiotherapy although reported cases remain too low to
recommend a therapeutic approach. However, CD30-based therapeutics might be a future option.
 2014 Elsevier B.V. All rights reserved.
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The ﬁrst breast implant procedures were performed in the 1960s
and, since then, between 5 and 10 million procedures have been
performed worldwide [1,2]. In 2012, 286,000 breast augmentation
procedures and 72,012 breast reconstructions were performed using
implants in the United States alone [2]. Whilst breast implant
surgery can confer ‘life-enhancing’ beneﬁts for women, it remains
unclear whether the breast implants are carcinogenic.
In the last two decades, a number of case reports have
documented the occurrence of anaplastic large cell lymphoma
(ALCL), a rare type of non-Hodgkin lymphoma (NHL), in the capsule
surrounding breast implants. This has led to the hypothesis that
ALCL may be a late complication of the procedure and reviews of
between 27 and 34 case reports have been conducted by various
medical and governmental institutions in an attempt to ascertain
the exact relationship between ALCL and breast implants [3–29].
However, very few publications have sought to examine the possible
mechanisms or evaluate the evidence underpinning this topic.
In this review we present an updated summary of the published
cases of iALCL (71 cases) and discuss potential mechanisms
towards the pathogenesis of this disease.
1.1. ALCL
Systemic ALCL is a T-cell lymphoma predominantly affecting
the paediatric and young adult patient population when
anaplastic lymphoma kinase (ALK) positive and adults (40–65
years) when ALK with a male predominance in both cases
(male:female ratio of 1.5:1) [30,31]. It can present at both nodal
and extranodal sites, the latter including skin, lung, liver, soft
tissue and bone [31–34]. Histopathologically, it is a heteroge-
neous disease with a number of morphological variant forms
including small cell, lymphohistiocytic, Hodgkin-like and com-
mon forms [35]. ALCL is further sub-divided into two provisional
entities, ALK positive and negative, the former being more
common [35].
1.1.1. ALCL, ALK+
ALCL, ALK+ has a relatively good prognosis with a 5 year overall
survival of 80% (70% when paediatric patients are excluded) and
whilst the rate of relapse is high (30%), most patients remain
sensitive to chemotherapy [36]. ALK is expressed in ALCL as the
consequence of a chromosomal translocation whereby the ALK
gene on chromosome 2 becomes juxtaposed to a variety of partner
genes, but most commonly Nucleophosmin (NPM) on chromosome
5 [37]. The fusion gene retains the oligomerisation domains of NPM
together with the kinase domain of ALK resulting in the productionof a constitutively active intracellular tyrosine kinase activating a
plethora of signal transduction pathways key amongst which is
STAT3 [38,39]. Hyperactive ALK-induced signalling is key to
cellular transformation and small molecule inhibitors of this
protein hold much promise in the future treatment of this disease
[40].
1.1.2. ALCL, ALK
In contrast to ALCL ALK+, ALCL ALK cases have a poor prognosis
with an overall survival at 5 years of 49% [31]. Unlike for ALCL,
ALK+, the driving oncogenic events in ALCL, ALK are unknown as
there are no detectable recurrent cytogenetic events although
recently a translocation, t(6;7)(p25.3;q32.3) resulting in down-
regulation of DUSP22 has been detected in 18% of ALCL, ALK [41].
In addition events inactivating/inducing expression of genes
including PRDM1/BLIMP1, TNFRSF8, BATF3, and TMOD1 as well
as miRNA have been reported [41–44]. However, their relative
importance towards the pathogenesis of ALCL, ALK remains to be
determined.
1.1.3. Cutaneous ALCL
Cutaneous ALCL (C-ALCL; as opposed to systemic ALCL with
cutaneous involvement) belongs to the diagnostic category of
primary cutaneous CD30-positive T-cell lymphoproliferative dis-
orders [35]. Like ALCL, ALK it mostly affects adults with a median
age of 60 and is also ALK with patients having a favourable
prognosis with a 10 year survival rate of 90% [45,46].
1.1.4. ALCL of the breast (non-implant associated)
If ALCL, ALK is rare, then ALCL presenting in the breast is
almost non-existent. Of the 27 worldwide reported cases of non-
implant associated ALCL, one third are ALK and two thirds are
ALK+ [15]. The mean age of the patients at disease presentation is
50 for the ALK and 37 years for the ALK+ cases and the disease
presents as a diffuse spread throughout the breast tissue [15].
Due its extreme rarity, prognosis of ALCL of the breast is
unknown.
1.1.5. ALCL associated with breast implants
Implant-related ALCL (iALCL) occur in close proximity to the
implant capsule, either as part of the periprosthetic ﬂuid or in the
capsule itself [6,15,47–49]. From our review, the typical patient
with iALCL is 50 years old, previously healthy (although half of
patients had reconstructive surgery following breast cancer) and
received a silicone-coated implant a decade before for cosmetic
purposes (Table 1). The most common presenting complaint was
late seroma 10 years following implantation (range: 1–32 years)
[22,50–52]. This was followed by the presence of a palpable mass
Table 2
Summary of clinical presentation and treatments used.
Presentation
Seroma 37
Mass 22
Contracture 10
Pain 11
Inﬂammation 7
Swelling 13
B Symptoms 2
Lymphadenopathy 2
Treatment
Surgery
Implant removal 51
Capsulotomy 36
No surgery 4
Not reported 14
Chemotherapy
CHOP 26
ICE 3
ESHAP 2
GIV 2
Not reported 28
No chemotherapy 12
Radiotherapy
Yes 30
No 28
Not reported 13
Follow-up (weeks)
Range 1–52
Mean 15
Resolved 41
Recurrence/relapse 3
Deceased 5
Not reported 22
Table 1
Summary of patient and implant characteristics.*
Number of cases 71
Patient characteristics
Age
Range 28–87
Mean 51.49
Previous breast cancer
Yes 28
No 29
Not reported 14
Previous lymphoma
Yes 5
No 52
Not reported 14
Implant characteristics
Coating material
Silicone 45
Polyurethane 2
Not reported 24
Filling
Silicone 24
Saline 30
Not reported 17
Implant leak 7
Indication
Cosmetic 25
Reconstructive 13
Not reported 29
Years between implant and ALCL
Range 1–32
Mean 9.97
* Note that ﬁve patients had a previous history of lymphoma. Of these,
information on the subtype of disease was only provided for 3 cases: 1. Hodgkin’s
Lymphoma; 2. ALK+ cutaneous ALCL; 3. ALK cutaneous ALCL.
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of the extent of capsular contraction ranging from I to IV, I being
relatively normal to IV, the breast being hard, painful to the touch
and abnormal in appearance). Very few complained of systemic
symptoms (Table 2). Diagnosis was most commonly established
with the triple assessment (clinical evaluation, imaging and
cytology). Fig. 1 shows a typical histopathological presentation
of iALCL whereby hallmark lymphoma cells are apparent as is
positive cell surface and cytoplasmic staining for CD30. Most
women had early stage disease which responded favourably to
surgery, chemotherapy and radiation possibly due to the removal
of carcinogenic stimuli with implant removal and capsulotomy
(Table 2) [15,22,23,47–49,53,54]. However, an unfortunate few
have been reported to relapse and die following disease progres-
sion (Table 2).
Typically iALCL is ALK- as shown in Fig. 1d although one case
has been reported as ALK+ [21]. Interestingly, in the example
presented in Fig. 1, weak staining for ALK is apparent and this
correlates with an increase in ALK gene dosage to 5 copies as
assessed by FISH using an ALK break apart probe; ALK ampliﬁca-
tion has been implicated in other cancers, most notably
neuroblastoma and therefore the relevance of ALK to iALCL
remains to be fully elucidated.
2. Is breast implant-associated ALCL a distinct disease entity?
2.1. Comparison of iALCL with systemic ALCL, ALK+ and ALK
Histopathologically, iALCL presents similarly to systemic ALCL
regardless of ALK status although given the predominance of ALK-
cases it likely better aligns with ALCL, ALK especially given the
older diagnostic age. However, survival rates are higher as is the
case for ALCL, ALK+ and therefore iALCL is probably best describedas another provisional entity of ALCL hence giving rise to four
categories, iALCL, C-ALCL, ALCL ALK+ and ALCL ALK.
2.2. Comparison of NHL of the breast between patients with and
without breast implants
NHLs in patients without breast implants are a histologically
heterogeneous group of lymphomas mostly accounted for by
diffuse large B-cell and follicular sub-types; T-cell lymphomas are
rare [11,27]. In contrast, NHLs in breast implant patients are
histopathologically uniform (i.e. >80% are ALCL) and outnumber
their non-ALCL counterparts by approximately 5–1 [6,15,47–49].
However, ALCL has also been reported in the breast in the context
of patients that do not have breast implants but there are still
signiﬁcant differences in disease presentation in both scenarios.
For example, the majority of iALCL are ALK (61/62 reported)
whereas two thirds of those not associated with breast implants
are ALK+ suggestive of differing mechanism of tumorigenesis
[6,15,47–49].
In addition, all breast iALCL occur in close proximity to the
implant capsule whereas those in patients without implants are
diffuse [15]. Lastly, whilst the diagnosis of ALCL of the breast is of a
low incidence, most of these cases have been reported in
association with breast implants (42/69). These data support the
proposition that NHLs of the breast are distinct depending on the
patient class in which they appear.
2.3. Incidence of ALCL in breast implants versus other bioprostheses
Notwithstanding the above biological distinctions between
iALCL and those occurring in the absence of breast implants, there
are counterarguments to the proposition that there is a speciﬁc
association between breast implants and a certain subtype of ALCL,
Fig. 1. Histopathological presentation of breast implant-associated ALCL showing large hallmark cells with pleomorphic nuclei and abundant cytoplasm. (a) A 20 H&E
image. (b) A 100 H&E image taken under oil immersion showing hallmark cells (indicated by arrows). (c) Immunohistochemistry for cell surface CD30 expression, 40. (d)
ALK staining 40. (e) Interphase FISH using an ALK dual-colour break-apart probe (Vysis LSI1) showing ﬁve copies in most nuclei.
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been observed in breast implant patients as compared to the
general population may simply be attributable to a higher overall
incidence of lymphomas and cancer in patients with prostheses in
general.
The occurrence of periprosthetic NHL (mostly B-cell lympho-
ma) has been reported in the setting of orthopaedic and cardiac
prostheses [55–61]. Epidemiological studies comparing cancer
rates between patients with joint replacements and the general
population have found similar rates of NHL in patients with hip and
knee prostheses to that observed in patients with breast implants
(SIR = 0.98–1.16 and 1.20–2.19, respectively) [58,59,62]. However,these studies included 95% conﬁdence intervals of 1.0, so the
association between orthopaedic devices and cancer risk is still
unclear. The preliminary conclusions from these orthopaedic
studies appear to be closely aligned with the ﬁndings in breast
implant literature that there may be a small but statistically
insigniﬁcant risk of NHL in patients with prosthetic devices.
This evidence examined alone seems to suggest that the
development of lymphomas around prosthetic devices may be a
generalized pathological phenomenon arising from the prolonged
presence of foreign materials, rather than a phenomenon that is
unique to breast implants per se. However, although NHLs (mostly
B-cell lymphomas), sarcomas and other soft tissue tumours have
X. Ye et al. / Mutation Research 762 (2014) 123–132 127been noted to occur in close proximity to prosthetic devices, there
has only ever been one reported case of ALCL in a non-breast
prosthesis (a stainless steel plate) [59]. These facts support the idea
that iALCLs occur virtually exclusively in the context of breast
implants.
2.4. Cancer rates in breast implant patients versus the general
population
Existing literature suggests that NHLs in general account for
between 0.04 and 0.5% of all breast malignancies [27]. In contrast, a
case–control study conducted by de Jong et al. [6] estimated the
incidence of ALCL in the breast to be between 0.0001% and 0.0003%
of all women with breast prostheses per year. These results
represent a relative risk of 18.2 that ALCL will occur in women with
breast implants compared to those without breast implants,
although it is noted that the absolute risk is still extremely low at
between 1:500,000 and 1:3,000,000 patients per year according to
existing studies [6,29]. These ﬁgures are yet to be conﬁrmed with
further studies and, with an increasing global awareness of this
disease, it is possible that the reported incidence of iALCL may
change in light of updated numbers of case reports and will need to
be re-evaluated when the corresponding registry data becomes
available.
Despite these ﬁndings, a counterargument to the association of
breast implants and ALCL is that the breast implant population
experiences a higher overall incidence of cancer than the general
population, such that the elevated incidence of ALCL in women
with breast implants is no more than a ‘chance’ observation.
According to the results of our review, this does not appear to be
the case.
We identiﬁed six epidemiological papers that compared the risk
of cancer between patients with breast implants and the general
population [63–70]. In 2001, Brinton et al. [63] retrospectively
analyzed the incidence of cancer in 13,488 patients with breast
implants and found that malignancies of the cervix (SIR = 3.18),
vulva (SIR = 2.51), stomach (SIR = 2.65) and brain (SIR = 2.16), as
well as leukaemia (SIR = 2.19), occurred with greater frequency in
breast implant patients than in the general population. However,
the paper conceded that the increased relative risk of these cancers
was most likely attributable to lifestyle differences between the
two populations rather than the presence of breast implants.
One year later, a Finnish study compared the rate and stage of
cancer in 2171 breast implant patients recruited from private
plastic surgeries against the Finnish national registry. The study
found no evidence that cancers in the implant population occurred
at a higher rate or were at a more advanced stage than in the
general population (SIR = 0.90), with the exception of non-
melanoma skin cancer (SIR = 1.1) which was again attributed to
possible lifestyle factors between the two patient populations [68].
These results were echoed in four other studies by Friis et al.
(SIR = 0.70), Deapen et al. (SIR = 0.69), McLaughlin (SIR = 1.0) and
Lipworth et al. (SIR = 0.95) [64–66,70].
Ultimately, none of the six studies found any increase in the
incidence of breast cancer or lymphoma compared to the general
population. In fact, the majority of these studies (i.e. SIR < 1.0) seem
to suggest that cancer rates are lower in breast implant patients than
the general population. Accordingly, based on the available
evidence, it does not seem that the disproportionate frequency
with which ALCL has been observed in breast implant patients is the
result of higher cancer rates in the breast implant population.
Furthermore, overall cancer rates have also been extensively
examined in the setting of other bioprostheses, such as joint
replacements, through data collected in national registries [60,71–
74]. Although the conclusions of these reports are still the subject of
debate, it appears that patients with hip and knee prosthesis mayhave an elevated risk of malignancy compared to the general
population [60,71]. This in turn implies that breast implants may in
fact have lower rates of malignancy compared with orthopaedic
prostheses although the age group and selection biases between the
two populations preclude a direct comparison of relative cancer risk.
3. What is (are) the mechanism(s) driving tumorigenesis for
breast implant associated ALCL?
3.1. Chronic inﬂammation and the inﬂammatory milieu
Inﬂammation has been heralded as the seventh hallmark of
cancer [75]. Epidemiological evidence suggests that chronic
inﬂammatory states exhibit higher incidences of cancer [75,76].
Relevant examples include the association of T-cell lymphomas
with coeliac disease, primary thyroid lymphoma with Hashimoto’s
thyroiditis, and marginal zone B-cell lymphomas with hepatitis C
to list just a few. Conversely, non-steroidal anti-inﬂammatory
medications are associated with a lower incidence of some cancers
[75]. Although the precise mechanisms by which inﬂammation
facilitates tumorigenesis remains unclear, it has been suggested
that the dysregulated stromal microenvironment present in
unresolved inﬂammation induces genetic instability through
DNA injury and microsatellite instability, activates maladaptive
homeostatic responses and dormant transcription factors, and
subverts the immune surveillance against cells exhibiting pre-
cancerous change [75,76].
In the setting of iALCL, breast implant-associated NHL are most
commonly isolated in the ﬁbrotic capsule and seroma ﬂuid
surrounding the implant [77]. The formation of these capsular
tissues is in itself an inﬂammatory foreign body reaction resulting
from the activation of macrophages, ﬁbroblasts, and expansion of T
lymphocytes (Fig. 2) [77–83]. Indeed, the expansion of inﬂamma-
tory T-lymphocytes may be the source of iALCL whereby tumour
cells express cell surface markers typically associated with an
activated phenotype; tumour cells express the activation marker
CD30 and produce cytotoxic molecules such as Perforin and
Granzyme B [35]. Likewise, breast iALCL often express the same or
similar surface markers indicative of a transformed and activated
T-cell origin [22,47,54]. In further evidence, 3 cell lines have been
developed to represent this disease and all 3 express CD30,
produce Granzyme B and are of a T-cell phenotype as evidenced by
the presence of clonal T-cell receptor rearrangements [84].
Interestingly, a recent review by Miranda et al. [29] suggested
that there may be two subtypes of iALCL. First, iALCL of limited
disease with no discrete tumour mass have been observed to achieve
high rates of disease regression following treatment with capsu-
lotomy, suggesting that this subset of iALCL may represent
lymphoproliferations which are still very much dependent on the
antigenic stimulus for survival and expansion and therefore may be
amenable to a more conservative therapeutic approach of capsu-
lotomy alone [29]. Indeed, the three aforementioned iALCL-derived
cell lines are still dependent on IL2 for growth in vitro [84]. Whilst
this does not equate to spontaneous involution of residual tumour
cells left within patients after implant removal, it supports the
clinical observation that iALCL with limited disease may be clonal
but not autonomous.
However, in the remaining cases of iALCL, a higher proportion of
patients continue to progress and even die from their disease
despite surgery, suggesting that these cases of iACLC may have
become independent of the antigenic stimulus and have perhaps
acquired genetic mutations enabling autonomous survival. The
identity of the driving genetic events remains to be determined but
activating Notch mutations have been implicated [84].
Furthermore, chemotherapy was not shown in this review of 60
patients to improve overall progression-free survival at a mean
Fig. 2. Mechanisms of iALCL pathogenesis. A foreign body reaction in the host results in the formation of a ﬁbrous capsule around the implant. This process begins at
implantation as the implant is almost immediately covered, after its insertion, by a thin ﬁlm of protein. Shortly after this, a ﬁbrous matrix develops from the periprosthetic
thrombus. This in turn triggers an inﬂammatory cascade through the intrinsic, extrinsic ﬁbrinolytic, complement and kinin pathways, resulting in the activation of
macrophages, lymphocytes and ﬁbroblasts and ultimately culminating in a foreign body reaction against the implant material and the formation of a ﬁbrous capsule. The
chronic presence of a foreign body can result in the prolonged stimulation of lymphocytes, thereby causing delayed hypersensitivity reactions, aberrant wound healing and,
over time, the expansion of T-cells. One might envisage a scenario whereby chronic inﬂammation leads to the expansion and continued proliferation of an activated T-cell
pool which in time acquires mutations allowing cellular transformation and may become independent of the antigenic stimulus for growth.
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regression of disease without treatment, lending additional
support to the notion that the biological stimulus of the implant
and peri-capsular tissue may be the driving force underpinning the
pathogenesis of iALCL [29]. However, we do stress that these
results need to be interpreted with due caution given the
limitations with analysing case report data.
3.2. Inﬂammatory oncotaxis and immunological escape
Inﬂammatory oncotaxis refers to the attraction to and
activation of circulating neoplastic cells within a host by an
inﬂamed tissue space. This concept was ﬁrst described by Paget
in 1889 who wrote ‘‘When a plant goes to seed, its seeds are
carried in all directions. . .but they can only live and grow if they fall
on congenial soil.’’ [85]. Since then, a number of authors have
described instances of late tumour recurrence in inﬂamed
tissues distant to the site of origin. Of particular interest are case
reports of delayed metastasis to and development of lymphomas
around ﬁbrous pockets surrounding cardiovascular prostheses, a
scenario that is remarkably similar to the seeding of ALCL
tumour cells in the ﬁbrous capsule and periprosthetic ﬂuid
around breast implants [61,86–88]. It has been suggested thatﬁbrotic tissues provide the necessary stromal support and
extracellular matrix for tumours to progress and thus providing
the ‘congenial soil’ on which circulating and transformed cells
can ‘seed’.
The ﬁbrous capsule surrounding breast implants may facilitate
tumour escape from the immune system. The importance of the
immune system in tumour suppression is well evidenced by both
epidemiological and experimental models where immune-deﬁ-
cient hosts develop or can be induced into developing malignan-
cies [89]. Interestingly, the majority of these malignancies are
lymphomas [89].
‘Immunosurveillance’ is the detection and destruction of
circulating precancerous cells which have escaped intrinsic
tumour suppression mechanisms. When the clearance of tumour
cells is incomplete, a state of temporary equilibrium arises
between continued tumour evolution and immune elimination
of tumour cells. This immunological ‘arms race’ between the
tumour and the host is known as ‘immunoediting’ and tumours can
thus remain dormant for years until the equilibrium is disturbed,
resulting in tumour escape [76,89]. The provision of a permissive
mesenchymal microenvironment has been hypothesized to be a
critical step in providing tumours with a congenial environment
from which to evade the immune system through:
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tion of T lymphocytes, expression of inhibitory molecules,
down-regulation of MHC molecules [89,90];
(2) Inhibition of immune-inﬁltration through down-regulation of
adhesion molecules and the formation of physical barriers to
antigen presentation [90];
(3) Stimulating the expression of immunosuppressive and anti-
apoptotic factors produced by tumours [89].
(4) Inhibition of immune-inﬁltration through down-regulation of
adhesion molecules and the formation of physical barriers to
antigen presentation [90]; and
(5) Stimulating the expression of immunosuppressive and anti-
apoptotic factors produced by tumours [89].
The ﬁbrous capsule and periprosthetic ﬂuid in which the
majority of iALCL are found may provide such a friendly micro-
environment, although it is not possible to determine based on
available information, whether the potential mechanism is related
to tumours in distant tissues colonizing the breast capsule via
oncotaxis, or if clonal expansions of tumour cells arising at the site
of the implant are encouraged to remain in the area. Both
mechanisms are possible although most proponents of this theory
believe that the former is more plausible.
3.3. Immunogenicity of implants
If iALCL is a distinct disease entity one would assume that device-
related factors of the implant likely contribute to disease
pathogenesis. Speciﬁcally, the composition and/or texture of a
particular implant may be a ‘trigger’ and/or contribute to
tumorigenesis.
3.3.1. Composition – silicone
The majority of the implant devices reported in the 71 cases
examined contained silicone, either as a ﬁlling or as part of the
outer shell. Medical grade silicone is one of the most biologically
inert materials available and is used in a range of prosthetic devices
including pacemakers, ventriculo-peritoneal shunts and prosthetic
joints. However, over the last few decades, in light of reports of
autoimmune disease, silicone adenopathy and cancer occurring in
patients with silicone devices, there has been increasing concern
amongst both medical professionals and the wider community as
to the potential immunogenic and carcinogenic effects of silicone
when implanted in the human body [77,79,91–96].
There are two leading schools of thought as to the potential
mechanism through which silicone can exert toxicity. The ﬁrst
hypothesized mechanism is that silicone and silicone degradation
products are directly toxic to living tissues. In evidence, the
subcutaneous implantation of silicone gel has been shown to
induce plasmacytomas in genetically predisposed mice [22,23,97].
The implication of this ﬁnding is potentially alarming given that
silicone gels often ‘bleed’ through implant shells – indeed, silicone
particles have been reported to be present in the axillary lymph
nodes of over 90% of breast implant patients [77,94,98]; and once
spread into tissue, leaked silicone gel can augment the production
and release of interferon and TNF-a (in comparison to controls),
which in turn can cause granulomatous and ﬁbrotic reactions with
cytological abnormalities that, over time, may lead to the clonal
expansion of lymphocytes [94].
Even if the view is taken that silicone itself is inert, the
prolonged presence of silicone in living tissue may nevertheless
induce a foreign body response which can, over time, result in the
degradation of that silicone into its toxic breakdown products,
such as siloxane – which is an inducer of protein denaturation –
and platinum and silicates – which are known cellular irritants and
potential inducers of ﬁbrosis [77,79,81,82,93]. Each of these three
compounds have been detected in signiﬁcant concentrations in theﬁbrous capsule surrounding silicone implants and represents a
signiﬁcant toxicological issue for patients with silicone prostheses
[77]. Recently, cytometric studies by Wolfram et al. [99] on peri-
capsular lymphocytes have conﬁrmed the ﬁndings of earlier
histological studies that silicone and silicone breakdown products
induce, when combined with autologous proteins, an inﬂamma-
tory response.
3.3.2. Implant texture
In addition to the chemical properties of silicone, the particular
texture of an implant surface has also been suggested as a potential
factor in the development of late seromas and iALCL [47,48,100].
Since the early 1960s, animal models have demonstrated that
there are distinctive histological differences in the ﬁbroblastic
response to smooth implant surfaces and powdered implant
surfaces [101]. Speciﬁcally, the subcutaneous implantation of
smooth surfaces induces the formation of thick, densely packed
and laminar connective tissue ﬁbres which envelope the implant.
The tissue reaction to smooth surfaces is associated with intense
ﬁbroblastic and giant cell activity which regresses upon implant
removal. Cytologically, this more aggressive ﬁbroblastic reaction
can be explained by the observation that ﬁbroblasts cultured from
smooth implants are more effective in lowering the rate of
transforming growth factor 1 (TGF-1) – a cytokine which regulates
cellular proliferation – than their textured counterparts [102].
In contrast, the implantation of powdered surfaces – even into a
pre-formed tissue pocket around a smooth surface – results in the
formation of loose and irregularly-arranged collagen ﬁbres with
few active ﬁbroblasts but numerous giant cells, possibly as a result
of anoikis or apoptosis of the capsule lining due to its detachment
from its supportive matrix [77,80]. Unlike smooth surfaces,
powdered surfaces cannot easily be removed and thus the giant
cell response can remain indeﬁnitely (even after the removal of the
smooth surface backing) and cause chronic irritation to the
periprosthetic tissue [101].
Although the precise pathophysiological mechanism of double
capsules and late seromas remain the subject of speculation, recent
observations that these conditions occur almost exclusively in
patients with textured implants lend support to the proposition
that textured surfaces impede the adherence of cells to the implant
surface, thereby resulting in tenuous ‘Velcro-like’ scar tissue which
detaches with minor trauma [103]. The resulting ‘shear’ force
between the two dissected surfaces in turn leads to cellular
irritation, inﬂammation and seroma formation [103].
Based on the above observations, and the disproportionate
occurrence of late seromas in ALCL patients compared to the
general breast implant population (35.6% vs. 0.1%), the occurrence
of late seromas is widely regarded by the plastic surgery
community to be associated with the pathogenesis of ALCL
although no causal relationship has yet been deﬁned [103–105].
3.4. Subclinical infection as a carcinogen
Breast tissue is considered a ‘clean-contaminated’ surgical site
as its ducts and glands communicate with the external environ-
ment. In a study where intra-operative swabs were taken from
sterilized breast tissue, bacterial colonies were isolated in 38% of
specimens [106]. Furthermore, scanning electron microscopy of
swab-negative implants and capsules from women with capsular
contractures have demonstrated that 38.5% of implants with Baker
grade III/IV contractures are associated with a bioﬁlm of coagulase
negative bacteria compared to only 12.5% in patients with mild or
no contractures [107]. Also, the deliberate inoculation of implants
with staphylococcus in porcine models results in a 4.17-fold
increase in the incidence of grade III/IV contractures compared to
uncontaminated implants [108].
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that 16.1% of all new cancer diagnoses are attributable to infections
[109]. Indeed, there is a substantial body of evidence linking
prolonged infection with select pathogens to lymphoma formation
including helicobacter pylori and mucosa-associated lymphoid
tissue lymphoma, Epstein–Barr virus and Hodgkin lymphoma, and
Human Herpes Virus-8 and primary effusion lymphoma [109–
112].
However, a direct link between bacterial and/or viral contami-
nation and ALCL of any form has not yet been demonstrated.
Recently, 3 cell lines derived from iALCL were all determined to be
negative for EBV, HTLV and HPV [84]. Therefore, although there is
currently no deﬁnitive proof of an association between implant
infection and lymphoma formation, the induction of ALCL by a yet
to be deﬁned pathogen is a distinct theoretical possibility which
remains to be discounted. Applying the same train of thought, ALCL
has been reported in the context of insect bites whereby it is
assumed that antigens resulting from the bite drive infection, later
leading to lymphoma development derived from the inﬁltrating T-
cells – in these cases, ALCL is ALK+ and hence this likely also
contributes to disease pathogenesis [113]. The identity of these
antigens remains elusive but could be related to infection at the
site of the bite.
4. Therapeutic approaches
A number of treatments have been used in the reported cases
including implant removal and capsulotomy, lymph node dissec-
tion, chemotherapy, radiotherapy and even autologous stem cell
transplantation. However, given the small number of patients
analyzed, heterogeneity of therapies employed and limited length
of follow-up, it is difﬁcult to determine the speciﬁc effect of each
intervention for any achieved outcome.
The simplest approach is removal of the implant and its
associated ﬁbrotic capsule and there is evidence to suggest that
this procedure alone is sufﬁcient to remove disease particularly in
those patients with lymphoma restricted to the ﬂuid cavity bound
by the capsule [29]. Various chemotherapeutic regimens have also
been used although no signiﬁcant improvement in overall
progression-free survival has yet been demonstrated [29]. It
would appear from the lack of clinical or empirical evidence
guiding the use of chemotherapy of iALCL that most oncologists
have opted to treat their patients based on existing NHL protocols.
The most common regimen reported is CHOP (26/43 reported) and
most patients enter remission or resolution of their disease (41/49
reported) at a mean of 15 months follow-up (range 1–52). A small
proportion of treated individuals fail to respond to therapy and
questions have been raised about a more aggressive phenotype for
iALCL [3,5]. In particular, patients that present with a mass rather
than a disease conﬁned within the ﬁbrous capsule have a lower
rate of complete remission (p = 0.18)[29]. Similarly, the efﬁcacy of
radiation therapy is yet to be determined. This has led oncologists
in search of novel therapeutic options.
Aside from ALK positivity/negativity, elevated CD30 expression
is a deﬁning feature of all forms of ALCL and hence the CD30
biomarker is a highly promising target for therapies aimed at
modulating tumour cells [114]. Given that CD30 is generally not
expressed on circulating lymphocytes, therapies that target this
protein should have limited side effects and so several approaches
have been studied to utilize and exploit CD30 expression. Targeting
approaches have included radio-immunoconjugates, immunotox-
ins, immunoRNAses, immunokinases, and antibody drug con-
jugates (ADCs) [114]. Notably, in 2011 the ADC brentuximab-
vedotin (SGN35) was approved for patients with refractory and
relapsed Hodgkin lymphoma and ALCL. SGN 35 is composed of the
CD30 speciﬁc chimeric monoclonal antibody cAC10 combinedwith the potent Tubulin toxin monomethyl auristatin E [115].
Given the efﬁcacy of this drug initially in xenograft models and
then in phases I and II clinical trials it is now being incorporated
into the upfront management of CD30+ lymphoma [115]. It is likely
that the use of CD30 targeting agents will further enhance survival
as an adjunct to current ﬁrst line chemotherapeutics for patients
with all ALCL diagnostic entities including iALCL, where the
predominant subtype does not harbour the ALK translocation
amenable to tyrosine kinase inhibition. However, for those rare
cases of iALCL that do aberrantly express ALK, kinase inhibitors
might also be considered as a therapeutic approach. Many
inhibitors of the ALK protein are now in preclinical and clinical
development although the Pﬁzer compound Crizotinib has so far
been the most extensively employed having been approved by the
FDA in 2011. Crizotinib shows efﬁcacy in the treatment of patients
with NSCLC expressing the chromosomal inversion protein
product, EML4/ALK. Indeed, Crizotinib also demonstrates efﬁcacy
in patients with ALCL, ALK+ and some cases of neuroblastoma
whereby the ALK gene is either ampliﬁed or expressed as a point
mutation [116].
5. Conclusions
With an ever-growing database of ALCL cases occurring around
breast implants worldwide, it is becoming more apparent that
iALCL is very much a distinct clinical entity. We present a synopsis
of the possible pathophysiological mechanisms for tumorigenesis
based on the available basic science literature although there
remain many unanswered questions surrounding this rare disease
entity.
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